Rarecells Diagnostics

Rarecells Diagnostics

Partager

Rarecells Diagnostics develops and commercializes the ISET technology to isolate Circulating Tumor Cells for early cancer diagnosis and medical research.

Rarecells® Diagnostics was created in 2010 by Patrizia Paterlini Brechot, Professor of Cell Biology and Oncology, in order to make the scientific and technological advances developed by her team available to research teams and patients. Rarecells® Diagnostics’ core product is the patented ISET® (Isolation by SizE of Tumor cells) Technology. Rarecells® Diagnostics has the exclusive license of paten

Diagnosis of Circulating Cancer Cells (CCC) is Critical in Predictive Oncology 09/02/2015

Diagnosis of circulating cancer cells is critical in predictive oncology

Diagnosis of Circulating Cancer Cells (CCC) is Critical in Predictive Oncology A key issue with cancers that continue to have lower patient survivability rates, such as lung cancer, cervical cancer and colorectal cancer, is that they are often not diagnosed until later stages. Many times this means that cancer is not diagnosed until after it has metastasized, or spread to othe…

Isolation of Circulating Tumor Cells of All Types Without Loss is a Technical Challenge 06/02/2015

Isolation of circulating tumor cells of all types without loss is a technical challenge

Isolation of Circulating Tumor Cells of All Types Without Loss is a Technical Challenge Circulating Tumor Cells (CTCs) are cells from a primary tumor that shed into a patient’s bloodstream. These cells can often be detected years before a cancer reaches metastasis, the later stages of cancer in which it becomes more difficult to treat successfully. Detection of these cells in a patient…

Circulating tumor cells are present in blood for years before metastases develop 06/02/2015

Did you know that circulating cancer cells are present in the blood years before metastases?

Circulating tumor cells are present in blood for years before metastases develop It is widely accepted that the earlier cancer is diagnosed, the more likely a patient is to survive. The problem with the deadliest forms of cancer, such as lung, colorectal or cervical cancer among others, is that patients often remain asymptomatic until later stages. If these patients aren’t seein…

Q&A with Dr. Paul Hofman 05/02/2015

Here's a great interview with Dr. Paul Hofman regarding his paper on Sentinel Circulating Tumor Cells and early lung cancer diagnosis in COPD patients

Q&A with Dr. Paul Hofman Lead author Paul Hofman, MD, discusses the patient population and the 5 patients who were diagnosed early with lung cancer and treated successfully

ISET Paper is in the Top Ten at PLOS One 18/11/2014

We're thrilled that the latest paper validating the identification of circulating tumor cells for early diagnosis on lung cancer in patients with COPD is in the Top 10 at PLOS One!

ISET Paper is in the Top Ten at PLOS One The research study on the use of ISET by Rarecells to diagnose and treat lung cancer at the first signs of tumor growth is in the Top 10 of most viewed research papers at the Public Library of Science (PLOS) ONE open-access journal.

ISET in the news 18/11/2014

Check out all the latest news on Rarecells and ISET!

ISET in the news ScienceDaily Lung Disease News Lung Cancer News Today Medical Lab Observer Journal Clinical Lab Products Respiratory Therapy BioSpace BioScienceTechnology.com NewsMaxHealth Herald

Could Circulating Tumor Cells Narrow Lung Cancer Screening to Those at Greatest Risk ? 18/11/2014

As Medicare announces funding for CT scan screening - keep in mind that Circulating Tumor Cells have the potential to help diagnose those patients at greatest risk.

Could Circulating Tumor Cells Narrow Lung Cancer Screening to Those at Greatest Risk ? On Nov. 10,2014, the U.S. Centers for Medicare & Medicaid Services (CMS) announced that it will fund low-dose helical computerized tomography (CT) screening for those at high risk for lung cancer, specifically those aged 55-74 who are defined at “heavy smokers” (1 pack per day for the last 30 years…

Lung cancer diagnosed before it is detected by imaging 04/11/2014

From Science Daily! Exciting coverage of the new study with a focus on diagnosis of lung cancer before it is detected by imaging. http://goo.gl/kt0Eox

Lung cancer diagnosed before it is detected by imaging It is possible to detect, in patients at risk of developing lung cancer, early signs of the disease in the form of circulating cancer cells, several months, and in some cases several years, before the cancer becomes detectable by CT scanning, researchers report. This warning could play a key role in…

Detection of Cancer by Circulating Tumor Cells Leads to Rapid Early-Stage Treatment without... 02/11/2014

Check out our latest blog post! We're excited about this important validation early cancer detection via circulating tumor cells! http://www.isetbyrarecells.com/detection-cancer-circulating-tumor-cells-leads-rapid-early-stage-treatment-without-recurrence/

Detection of Cancer by Circulating Tumor Cells Leads to Rapid Early-Stage Treatment without... Earlier this year, the New York Times published an article on research into the detection of asymptomatic or “silent” cancers by finding circulating tumor cells (CTCs), a method sometimes referred to as “liquid biopsy.” In that article, noted NYT science reporter Andrew Pollack wrote: “For all the p…

Vous voulez que votre école soit école la plus cotée à Paris ?

Cliquez ici pour réclamer votre Listage Commercial.

Emplacement

Téléphone

Adresse


101 Rue De Sèvres
Paris
75006